Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw.
Bisphosphonate
MRONJ
Pharmacoepidemiology
Weight dose deposited
Journal
Maxillofacial plastic and reconstructive surgery
ISSN: 2288-8101
Titre abrégé: Maxillofac Plast Reconstr Surg
Pays: England
ID NLM: 101633100
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
11
06
2019
accepted:
24
06
2019
entrez:
13
8
2019
pubmed:
14
8
2019
medline:
14
8
2019
Statut:
epublish
Résumé
The aim of this study was to investigate clinical and pharmacoepidemiologic characteristics of medication-related osteonecrosis of the jaw. The study population is comprised of 86patients who were diagnosed with ONJ at Ewha Womans University Mokdong Hospital from 2008 to 2015. Factors for epidemiologic evaluation were gender, age, location of lesion, and clinical history. The types of bisphosphonates, duration of intake, and the amount of accumulated dose were evaluated for therapeutic response. Clinical symptoms and radiographic images were utilized for the assessment of prognosis. Among the 86 patients, five were male, whereas 81 were female with mean age of 73.98 (range 45-97). Location of the lesion was in the mandible for 58 patients and maxilla in 25 patients. Three patients had both mandible and maxilla affected. This shows that the mandible is more prone to the formation of ONJ lesions compared to the maxilla. ONJ occurred in 38 cases after extraction, nine cases after implant surgery, six cases were denture use, and spontaneously in 33 cases. Seventy-six patients were taking other drugs aside from drugs indicated for osteoporosis. Most of these patients were diagnosed as osteoporosis, rheumatic arthritis, multiple myeloma, or had a history of cancer therapy. Higher weighted total accumulation doses were significantly associated with poorer prognosis ( Dose, duration, route, and relative potency of bisphosphonates are significantly associated with treatment prognosis of osteonecrosis of the jaw.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to investigate clinical and pharmacoepidemiologic characteristics of medication-related osteonecrosis of the jaw.
METHODS
METHODS
The study population is comprised of 86patients who were diagnosed with ONJ at Ewha Womans University Mokdong Hospital from 2008 to 2015. Factors for epidemiologic evaluation were gender, age, location of lesion, and clinical history. The types of bisphosphonates, duration of intake, and the amount of accumulated dose were evaluated for therapeutic response. Clinical symptoms and radiographic images were utilized for the assessment of prognosis.
RESULTS
RESULTS
Among the 86 patients, five were male, whereas 81 were female with mean age of 73.98 (range 45-97). Location of the lesion was in the mandible for 58 patients and maxilla in 25 patients. Three patients had both mandible and maxilla affected. This shows that the mandible is more prone to the formation of ONJ lesions compared to the maxilla. ONJ occurred in 38 cases after extraction, nine cases after implant surgery, six cases were denture use, and spontaneously in 33 cases. Seventy-six patients were taking other drugs aside from drugs indicated for osteoporosis. Most of these patients were diagnosed as osteoporosis, rheumatic arthritis, multiple myeloma, or had a history of cancer therapy. Higher weighted total accumulation doses were significantly associated with poorer prognosis (
CONCLUSION
CONCLUSIONS
Dose, duration, route, and relative potency of bisphosphonates are significantly associated with treatment prognosis of osteonecrosis of the jaw.
Identifiants
pubmed: 31403036
doi: 10.1186/s40902-019-0210-8
pii: 210
pmc: PMC6646625
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Clin Oncol. 2001 Jan 15;19(2):558-67
pubmed: 11208851
J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61
pubmed: 12183663
J Clin Oncol. 2002 Sep 1;20(17):3719-36
pubmed: 12202673
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
pubmed: 12359855
J Clin Oncol. 2003 Nov 1;21(21):4042-57
pubmed: 12963702
J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
pubmed: 12966493
J Oral Maxillofac Surg. 2004 May;62(5):527-34
pubmed: 15122554
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
pubmed: 15173273
Cancer. 2004 Jun 15;100(12):2613-21
pubmed: 15197804
N Engl J Med. 2004 Jul 8;351(2):190-2; author reply 190-2
pubmed: 15250063
J Clin Oncol. 2005 Dec 1;23(34):8580-7
pubmed: 16314620
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):433-41
pubmed: 16997108
Laryngoscope. 2007 Jan;117(1):30-4
pubmed: 17202926
J Oral Maxillofac Surg. 2007 Mar;65(3):369-76
pubmed: 17307580
J Oral Maxillofac Surg. 2007 Mar;65(3):415-23
pubmed: 17307586
Bone. 2007 Sep;41(3):318-20
pubmed: 17572168
J Dent Res. 2007 Nov;86(11):1022-33
pubmed: 17959891
Oral Oncol. 2009 Jul;45(7):645-6
pubmed: 18715813
Laryngoscope. 2009 Feb;119(2):323-9
pubmed: 19172621
Am J Med. 2009 Feb;122(2 Suppl):S33-45
pubmed: 19187811
J Oral Maxillofac Surg. 2009 Mar;67(3):593-601
pubmed: 19231786
J Oral Maxillofac Surg. 2010 Feb;68(2):243-53
pubmed: 19772941
J Clin Oncol. 2009 Nov 10;27(32):5356-62
pubmed: 19805682
J Rheumatol. 2009 Dec;36(12):2780-7
pubmed: 19884275
Aust Endod J. 2009 Dec;35(3):119-30
pubmed: 19961450
J Bone Miner Res. 2010 Jun;25(6):1337-49
pubmed: 20200938
Am J Pathol. 2010 Jul;177(1):280-90
pubmed: 20472893
J Cancer Res Clin Oncol. 2010 Aug;136(8):1117-24
pubmed: 20508948
J Craniomaxillofac Surg. 2011 Jun;39(4):272-7
pubmed: 20580566
Am J Med. 2010 Nov;123(11):1060-4
pubmed: 20851366
J Am Dent Assoc. 2010 Nov;141(11):1365-70
pubmed: 21037195
J Bone Miner Metab. 2012 Mar;30(2):171-82
pubmed: 21858474
J Oral Pathol Med. 2012 Mar;41(3):214-21
pubmed: 21958312
J Am Dent Assoc. 2011 Nov;142(11):1243-51
pubmed: 22041409
Clin Cases Miner Bone Metab. 2007 Jan;4(1):53-7
pubmed: 22460754
Med Oral Patol Oral Cir Bucal. 2013 Sep 01;18(5):e752-8
pubmed: 23722119
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
Acta Otorrinolaringol Esp. 2015 May-Jun;66(3):139-47
pubmed: 25308796
J Bone Miner Res. 2015 Jan;30(1):3-23
pubmed: 25414052
Rom J Morphol Embryol. 2014;55(4):1511-4
pubmed: 25611290
Rom J Morphol Embryol. 2015;56(2):613-8
pubmed: 26193239
Rom J Morphol Embryol. 2016;57(1):319-22
pubmed: 27151729
Rom J Morphol Embryol. 2016;57(2 Suppl):715-718
pubmed: 27833963
J Clin Densitom. 2017 Jan - Mar;20(1):8-24
pubmed: 27956123
Eur J Clin Pharmacol. 2017 May;73(5):517-523
pubmed: 28188332
Clin Oral Investig. 2018 Mar;22(2):597-615
pubmed: 29332231
Rom J Morphol Embryol. 2017;58(4):1541-1547
pubmed: 29556655
Rom J Morphol Embryol. 2018;59(1):113-119
pubmed: 29940618
J Clin Invest. 1996 Jun 15;97(12):2692-6
pubmed: 8675678